Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
about
Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World.Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenAddressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels.
P2860
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@ast
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@en
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@nl
type
label
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@ast
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@en
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@nl
prefLabel
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@ast
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@en
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@nl
P2093
P2860
P356
P1433
P1476
Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
@en
P2093
Matthias Schwab
Michel Eichelbaum
Werner Schroth
in cooperation with the AGO TRAFO Comission
P2860
P356
10.1159/000114642
P577
2008-02-22T00:00:00Z